NCT06579144 - Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

October 28, 2025

Conditions

Hemophilia A

Interventions

DRUG

Efanesoctocog alfa

Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)

Trial Locations (7)

RECRUITING

Sobi Investigational site, Frankfurt

RECRUITING

Sobi Investigational Site, Oldenburg

RECRUITING

Sobi Investigational Site, Milan

NOT_YET_RECRUITING

Sobi Investigational Site, Naples

RECRUITING

Sobi Investigational Site, A Coruña

RECRUITING

Sobi Investigational Site, Valencia

RECRUITING

Sobi Investigational Site, Zaragoza